 SAN DIEGO and CALGARY, Alberta , May 8, 2020 CNW -- Oncolytics Biotech Inc. ONCY ONC.TO, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2020 . Despite these challenges, we have successfully progressed our clinical objectives, said Dr. Matt Coffey , President and CEO of Oncolytics Biotech Inc. The first part of 2020 saw positive clinical updates not only in our breast cancer program but also in pancreatic, colorectal, and multiple myeloma. Through our collaborations with academia, the National Cancer Institute, and industry partners, including Roche, Pfizer, and Merck, we have been able to demonstrate that pelareorep is a potent stimulator of both the innate and adaptive immune response across a spectrum of malignancies. 